{
    "2019-04-16": [
        [
            {
                "time": "",
                "original_text": "药明康德 资本运作“后遗症”",
                "features": {
                    "keywords": [
                        "药明康德",
                        "资本运作",
                        "后遗症"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【增减持】药明康德(2359.HK)遭Schroders减持23.42万股",
                "features": {
                    "keywords": [
                        "药明康德",
                        "Schroders",
                        "减持",
                        "23.42万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【权益变动】药明康德(02359-HK)被Schroders Plc减持23.42万股",
                "features": {
                    "keywords": [
                        "药明康德",
                        "Schroders Plc",
                        "减持",
                        "23.42万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业动态:复星医药引进细胞疗法研发管线",
                "features": {
                    "keywords": [
                        "医药生物",
                        "复星医药",
                        "细胞疗法",
                        "研发管线"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}